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arettes and belongs to a highly addictive class of drugs. Nicotine atten-
uates the neuroinflammation induced by microglial activation. However,
the molecular target(s) underlying anti-inflammatory action of nicotine
has not been fully understood. Considering the psychoactive substances
morphine, cocaine, andmethamphetamine act as xenobiotic-associated
molecular patterns and can be specifically sensed by the innate immune
receptor Toll-like receptor 4 (TLR4), here we sought to delineate whether
nicotine and/or its metabolite cotinine may be recognized by the innate
immune system via myeloid differentiation protein 2 (MD2), an acces-
sory protein of TLR4 that is responsible for ligand recognition. MD2-
intrinsic fluorescence titrations, surface plasmon resonance, and
competitive displacement binding assays with curcumin (MD2 probe)
demonstrated that both nicotine and cotinine targeted the lipopolysac-
charide (LPS; TLR4 agonist) binding pocket of MD2 with similar affin-
ities. The cellular thermal shift assay indicated that nicotine binding
increased, while cotinine binding decreased, MD2 stability. These bio-
physical binding results were further supported by in silico simulations.
In keeping with targeting MD2, both nicotine and cotinine inhibited
LPS-induced production of nitric oxide and tumor necrosis factor alpha
(TNF-a) and blockedmicroglial activation. Neither a pan nicotinic acetyl-
choline receptor (nAChR) inhibitor nor RNAi for nAChRs abolished the
suppressive effect of nicotine- and cotinine-induced neuroinflammation.
These data indicate that TLR4 inhibition by nicotine and cotinine at the
concentrations tested in BV-2 cells is independent of classic neuronal
nAChRs and validate that MD2 is a direct target of nicotine and cotinine
in the inhibition of innate immunity.
Keywords: nicotine; cotinine; Toll-like receptor 4; myeloid differentiation
protein 2; microglia; molecular dynamics simulationINTRODUCTION
Toll-like receptor 4 (TLR 4) is a conserved innate immune receptor.1
Together with the accessory protein myeloid differentiation protein 2
(MD2), TLR4 detects pathogen-associated molecular patterns (PAMPs),
damage-associated molecular patterns (DAMPs), and xenobiotic-associated
molecular patterns (XAMPs).2
Nicotine is the principal alkaloid of tobacco that is most closely linked to
the addictive properties of smoking.3 Nicotine attenuates neuroinflammation
induced by microglial activation in the central nervous system (CNS), an ac-
tion assumed to arise via classic nicotinic acetylcholine receptors
(nAChRs).4,5 The a7nAChR-microRNA-124 signaling axis6,7 has been re-
ported to mediate the cholinergic anti-inflammatory effect. However, the
molecular target(s) underlying the anti-inflammatory actions of nicotine arellnot fully understood. Considering the recent studies that the psychoactive xe-
nobiotics morphine,8 cocaine,9 and methamphetamine10 can be specifically
sensed by TLR4/MD2, we sought to delineate whether nicotine and/or its
metabolite cotinine may be recognized by the innate immune system via
TLR4/MD2. The results of biophysical binding, in silico simulations, and
cellular characterizations consistently showed that MD2 is a direct target
of nicotine and cotinine.RESULTS
Nicotine and cotinine bind to MD2
MD2, a co-receptor of TLR4, is responsible for ligand recognition.11 Fluo-
rescence quenching titration of MD2 was first performed to explore innate
immune recognition of nicotine and cotinine by TLR4. As shown in Figure 1A,
nicotine and cotinine binding each caused quenching of MD2-intrinsic
fluorescence. By fitting the titration curves with a one-site binding model,
dissociation constants (KD) of 12.3 ± 1.0 and 13.5 ± 1.0 mM were obtained
for nicotine and cotinine interacting withMD2, respectively. As a comparison,
roxithromycin, a compound used as a negative control in MD2 binding,12
showed negligible MD2 fluorescence quenching, demonstrating the specific
binding of nicotine and cotinine to MD2. Figure 1B presents the log (F0/F–1)
versus log ([ligand]/mM) plots. A stoichiometry of 1.18 ± 0.03 and a KD of
11.0 ± 1.6 mMwere obtained for the binding of nicotine toMD2; a stoichiom-
etry of 1.12 ± 0.02 and a KD of 13.4 ± 1.8 mMwere obtained for cotinine bind-
ing to MD2. These results justify the one-site binding model used for the
nonlinear least-square fit of the MD2 quenching data (Figure 1A). Protein A
was used as negative control protein and no apparent quenching of protein
A-intrinsic fluorescence was observed when titrating with nicotine/cotinine
(Figure S1), indicating that the interaction of MD2 with nicotine and cotinine
are specific. To further confirm the recognition of nicotine and cotinine by
MD2, surface plasmon resonance (SPR)was performed. Nicotine (Figure 1C)
and cotinine (Figure 1D) interacted withMD2with the KD values of 23.1 ± 1.2
and 14.1 ± 1.8 mM, respectively. The binding affinities determined by SPR
were slightly different from those derived from the protein-intrinsic fluores-
cence quenching assays. This is not surprising considering that the underly-
ing principles of these two methods are different.
Fluorescence probe curcumin binds to the lipopolysaccharide (LPS) bind-
ing pocket of MD2, and its fluorescence intensity enhances when binding to
MD2.13 As shown in Figure S2, nicotine and cotinine caused a concentration-
dependent decrease of curcumin fluorescence from the curcumin-MD2 com-
plex, suggesting that nicotine/cotinine replaces curcumin binding in the LPS
binding pocket of MD2. In contrast, the negative control compound roxithro-
mycin induced negligible decrease in curcumin fluorescence, again support-
ing that nicotine and cotinine specifically interact with MD2.The Innovation 2, 100111, May 28, 2021 1
Figure 1. Biophysical characterizations of nicotine and cotinine binding with MD2 (A) Titration curves of MD2-intrinsic fluorescence with increasing compound con-
centration. Excitation at 280 nm and emission at 337 nm (peak position) was plotted against the titrated compound concentration. Kd values of 12.3 ± 1.0 and 13.5 ± 1.0 mM
were derived by nonlinear least-squares fit of a one-site binding model for interacting with MD2. Roxithromycin, which has been shown to have no apparent binding affinity
to MD2, was used as the negative control compound. (B) The binding curves shown in (A) were plotted according to the equation: lg(F0/F1) versus lg ([compound]/mM).
Kd = 11.0 ± 1.6 mM and n = 1.18 ± 0.03 were derived for nicotine binding to MD2; Kd = 13.4 ± 1.8 mM and n = 1.12 ± 0.02 were derived for cotinine binding to MD2. (C and D)
SPR analysis of nicotine (C) and cotinine (D) binding to theMD2 protein. (E) STD-NMR of nicotine/cotinine (400 mM)with MD2 (4 mM). 1H NMR assignments of nicotine and
cotinine are also given. (F) Cellular thermal shift assay of MD2 with nicotine and cotinine. Nicotine binding increases MD2 thermal stability (DTm = 6.5C ± 1.6C), while








onSaturation transfer difference NMR (STD-NMR) spectroscopy allows the
detection of transient (fast) binding of small-molecule ligands to macromol-
ecule receptors and is a powerful tool for investigating the mild to weak
ligand-protein interaction (Kd>105M).14 Thiswas used to explore themo-
lecular recognition ofMD2with nicotine and cotinine. STD-NMRdirectlymea-
sures NMR signals from the ligand itself and shows only those protons from
the ligand that interact by saturation transfer from the protein, thus identifying
the chemicalmoieties of the ligand involved in binding.15 The STD-NMRspec-
trumobtained for the complex ofMD2withboth nicotine and cotinine and the
reference spectra of nicotine and cotinine are shown in Figure 1E. Strong STD
signals from cotinine were readily observable, which supports that cotinine is
an active ligand ofMD2. However, no STD signalswere observed for nicotine,
which disagrees with results from the MD2-intrinsic fluorescence quenching
titration and curcumin competitive displacement binding assays that nicotine
specifically interacts with MD2.
It should be noted that STD-NMR requires that the ligand-protein complex
is in fast exchange on the NMR timescale and relies on the rapid exchange
between the bound and free states.16 Although nicotine and cotinine bind
to MD2 with similar affinities, which are close to the upper limit of the
ligand-protein interaction (Kd = 10 mM) suitable for STD-NMR measurement,
most likely they behave differently on the MD2 conformation. It is quite
possible that nicotine binding stabilizes the MD2 conformation, which de-
creases the exchange rate of nicotine between the bound and the free states,
therefore leading to a false negative of STD-NMR.
To directly investigate the effects of nicotine and cotinine on MD2 confor-
mation stability and explore whether MD2 could be an endogenous target of
nicotine and cotinine in the cellular context, cellular thermal shift assay
(CETSA) was performed. CETSA is based on the discovery that protein
melting curves can be generated and that drug binding leads to very2 The Innovation 2, 100111, May 28, 2021significant shift of its melting temperature (Tm).
17 The purified MD2 protein
is very stable (Tm 80C).8 CETSA of purified MD2 protein showed nicotine
binding increased MD2 protein stability, whereas cotinine binding decreased
MD2 stability (Figure S3). Similar results were obtained for CETSA of endog-
enousMD2 in cell lysate (Figure 1F). Nicotine increased the Tm value of MD2
by 6.5C ± 1.6C (Figure 1F), which supports the speculation derived from
STD-NMR that nicotine binding stabilizes the MD2 conformation. In contrast
to nicotine, cotinine decreased MD2 stability (DTm = 4.2C ± 0.5C) (Fig-
ure 1F), which indicates that cotinine binding increases the MD2 conforma-
tion flexibility. Compared with nicotine, cotinine would be in faster exchange
between the bound and free states. Therefore, the STD-NMR spectrumof the
complex of MD2 and cotinine was observed while no STD signals were
measured for the nicotine-MD2 complex. Although nicotine and cotinine
behaved differently on the MD2 stability, CETSA data show that they directly
bind toMD2 in a cellular context. In all, these biophysical binding data suggest
that MD2 is a direct target of nicotine and cotinine.
Molecular recognition of nicotine and cotinine by MD2
To investigate how nicotine and cotinine interact withMD2, computational
simulations were performed. The best docking poses with lowest energy of
nicotine and cotinine interacting with MD2 are given in Figure 2A and 2B,
respectively. Nicotine and cotinine were both found to dock into the
conserved hydrophobic cavity ofMD2 and overlapwith the R30 chains of lipid
A, which is consistent with the curcumin competitive displacement binding
assay result that nicotine and cotinine bind to the LPS binding pocket of
MD2. The best docking poses were refined using MD simulations. The
root-mean-square deviation (RMSD) values of MD2 (Figure S4) reached sta-
bility during 100 ns of MD simulations. Protein flexibility revealed by RMSD
showed that the conformation of the MD2 bound to cotinine was morewww.cell.com/the-innovation
Figure 2. In silico simulation of nicotine and cotinine interacting with MD2 (A and B) Overlap of the best docking pose of nicotine (A) and cotinine (B) with lipid A. Nicotine
and cotinine occupied the LPS binding location (acyl chains R30). MD2 is shown as cyan cartoon; lipid A is shown as a green stick model; nicotine and cotinine are shown as
a cyan surface model. (C) Time evolution of the RMSD of nicotine (black) and cotinine (red) during the MD simulations at 310.15 K. (D) The changes of the ratio of the
hydrophobic SASA in the buried SASA of MD2 upon binding to nicotine and cotinine. Data were calculated based on the last 20 ns equilibrated MD trajectories at 310.15 K.
***p < 0.001, ****p < 0.0001. (E and F) The calculated binding mode of nicotine (E) and cotinine (F) with MD2 at 310.15 K. The ligand is shown as a stick model. MD2 is




Innovationflexible than that of MD2 interactedwith nicotine, which is agreement with re-
sults of the STD-NMR and CETSA. The RMSD of the ligands during MD sim-
ulations was also monitored (Figure 2C). Cotinine had much higher RMSD
values than nicotine. This result shows that cotinine is more flexible than
nicotine in the ligand-MD2 complex. Compared with nicotine, cotinine would
have a faster exchange between the free form and the MD2 bound state,
which supports the speculation derived from the STD-NMR experiment.
The detailed binding mode of nicotine and cotinine with MD2 was subse-
quently investigated. Figure 2D shows the representative pose of nicotine
binding toMD2 during the molecular dynamic simulations. The heterocycles
of nicotine were surrounded by hydrophobic residues L78, F119, F121, and
F151of MD2. The nitrogen of the pyridine moiety from nicotine interacted
with R90 and C133 of MD2 through polar interactions. Cotinine interacted
with F199 and F121 of MD2 by hydrophobic interactions, and the oxygen
of the carbonyl moiety formed polar interactions R90 and C133 (Figure 2E).
The binding free energies calculated using the MM-PBSA method showed
that nicotine (12.2 ± 0.2 kcal/mol) and cotinine (11.3 ± 0.1 kcal/mol)
had similar MD2 binding free energies, which is consistent with the biophys-
ical measurements of the KD values.
Solvent-accessible surface areas (SASA) were calculated to further inves-
tigate the ligand binding-induced conformational changes of MD2. The
SASA of MD2 did not change upon binding with nicotine or cotinine
(Figure S5A). Both the buried SASA (Figure S5B) and the exposed SASA
(Figure S5C) did not change upon interacting with nicotine or cotinine. Inter-
estingly, further analysis showed that nicotine binding increased the per-
centage of hydrophobic area in the buried SASA of MD2, while cotinine
decreased the ratio of hydrophobic area in the buried SASA (Figure 2F).
It should be noted that the hydrophobic residues prefer to be buried inside
owing the hydrophobic interactions, therefore increasing the folding and
stability of the protein.18 These in silico simulation results explicitly explainllthat nicotine binding increases MD2 stability while cotinine decreases MD2
stability.
Nicotine and cotinine inhibition of LPS-induced pro-inflammatory
factors in microglia BV-2 cells is independent of nAChRs
Microglia are CNS immunocompetent cells and are key mediators of neu-
roinflammation.19 To investigate the actions of nicotine and cotinine on neu-
roinflammation, the effects of nicotine and cotinine on LPS-induced signaling
and the downstream pro-inflammatory factors were measured in the BV-2
microglial cell line, which reproduces many of the responses of primary mi-
croglia with high fidelity.20 Nicotine and cotinine inhibited the LPS-induced
MyD88 recruitment to TLR4 and suppressed the formation of the TLR4/
MD2/MyD88 complex (Figures 3A and 3B). LPS stimulation significantly
increased the phosphorylation of IRAK1, IRAK4, IKKb, p65, and p38. Both
nicotine (Figures 3C and 3D) and cotinine (Figures 3E and 3F) significantly
inhibited the LPS-induced phosphorylation of these TLR4 signaling factors.
The effects of nicotine and cotinine on the LPS-induced downstream pro-
inflammatory factors were next investigated. Nicotine (Figure 4A) and cotin-
ine (Figure 4B) inhibited LPS-induced nitric oxide (NO) overproduction in a
concentration-dependent manner with half-maximal inhibitory concentration
values of 0.8 ± 0.1 and 0.5 ± 0.1 mM, respectively, which were in agreement
with previous reports that high concentrations (>1 mM) of nicotine were
needed for in vitro microglial cellular assays.21 Cell viability was also tested
by crystal violet staining assay, and no apparent cellular toxicities of nicotine
(Figure 4A) or cotinine (Figure 4B) were observed, even at a concentration of
1.6 mM. This eliminates the possibility of the observed inhibition of LPS-
induced pro-inflammatory factors by nicotine and cotinine being due to
cell death.
In addition to NO, the pro-inflammatory cytokines interleukin-6 (IL-6), Cy-
clooxygenase-2 (COX-2), and tumor necrosis factor alpha (TNF-a) were alsoThe Innovation 2, 100111, May 28, 2021 3
Figure 3. Cellular characterizations of nicotine and cotinine on TLR4 signaling BV-2 cells were administered 200 ng/mL LPS and the indicated concentration of nicotine or
cotinine for 1 h. (A and B) The co-immunoprecipitation of anti-TLR4 antibody. MD2, TLR4, andMyD88 were detected by western blotting. (C–F) The effect of nicotine (C and
D) and cotinine (E and F) on the LPS-induced phosphorylation of IRAK1, IRAK4, IKKb, p65, and p38. All experiments were performed three times independently, and data are








onmeasured by qRT-PCR. LPS stimulation significantly increased mRNA
expression of IL-6 (Figures 4C and 4D), COX-2 (Figures 4E and 4F), and
TNF-a (Figures 4G and 4H) relative to the control in 24 h, especially at the
6-h time point. Generally, nicotine and cotinine inhibited LPS-induced IL-6,
COX-2, and TNF-a. Nicotine and cotinine inhibited LPS-induced TNF-a
mRNA (Figures 4G and 4H) and protein (Figure S6) with similar kinetic pat-
terns. However, the kinetic profiles of nicotine and cotinine in inhibiting LPS-
induced IL-6 andCOX-2were different. At the 2-h time point, only IL-6mRNA4 The Innovation 2, 100111, May 28, 2021was inhibited by cotinine at concentrations of 0.8 and 1.6 mM. At the 6-h
time point, both 1.6 mM nicotine and cotinine suppressed LPS-induced IL-
6 and COX-2mRNAs. At the 24-h time point, cotinine inhibited LPS-induced
IL-6 and COX-2 mRNA expression in a concentration-dependent manner.
However, nicotine (0.8 and 1.6 mM) failed to inhibit LPS-induced IL-6 and
COX-2 mRNAs and the corresponding proteins (Figure S7) at the 24-h
time point. The expressions of IL-6, COX-2, and TNF-a cytokines are not
only controlled by the transcription factor nuclear factor kB (NF-kB). Severalwww.cell.com/the-innovation
Figure 4. The effect of nicotine and cotinine on the LPS-induced downstream pro-inflammatory factors BV-2 cells were administered 200 ng/mL LPS and the indicated
concentration of nicotine (A, C, E, and G) or cotinine (B, D, F, and H). Cellular viability and the pro-inflammatory factors NO (A and B), IL-6 mRNA (C and D), COX-2 mRNA (E
and F), and TNF-amRNA (G and H) were measured at three different time points in 24 h. All experiments were performed three to four times independently, and data are
given as themean ± SEM. #p< 0.05 versus the control; ##p< 0.01 versus the control; ###p< 0.001 versus the control; *p< 0.05 versus the LPS group; **p< 0.01 versus the




Innovationother factors are also involved in the regulating these genes (Figure S8). It is
not surprising that the compounds inhibiting NF-kB do not necessarily
inhibit the downstream cytokines with the similar kinetic patterns. In addi-
tion to pro-inflammatory factors, increased ROS and phagocytosis are
also hallmarks of microglial activation. As shown in Figure S9, LPS stimula-
tion increasedH2O2 (Figure S9A) and the phagocytic activity (Figure S9B) ofllBV-2 cells. These were inhibited by nicotine and cotinine in a concentration-
dependent manner. Together, these data show that nicotine and cotinine
inhibitmicroglial activation as reflectedby suppression of both LPS-induced
pro-inflammatory factor overproduction and microglial phagocytosis.
Nicotine and cotinine are classic agonists of nAChRs,22 amongwhich a7
nAChR and a4b2 nAChR are the evolutionarily oldest nAChRs andThe Innovation 2, 100111, May 28, 2021 5
Figure 5. Blockage of nAChRs by RNAi or chemical agent does not attenuate nicotine and cotinine inhibiting LPS-induced pro-inflammatory factors (A) Western blotting
analysis of a7 nicotinic receptor in a stable a7 RNAi cell line and mock RNAi cells. (B and C) The effect of nicotine (B) and cotinine (C) on the LPS-induced NO production in
a7 nicotinic receptor knockdown cells. (D and E) The effect of nonselective nAChR antagonist mecamylamine (Mec) on nicotine (D) and cotinine (E) blocking LPS-induced
NO overproduction. (F), the effect of Mec on nicotine and cotinine blocking LPS-induced TNF-a protein overproduction. Cells were treated with LPS (200 ng/mL) and the
indicated concentrations of nicotine/cotinine. After treatment for 24 h, supernatants were collected for NO assay and TNF-a ELISA. n = 3–4 independent experiments, and
data are given as the mean ± SEM. ##p < 0.01 versus the control; ###p < 0.001 versus the control; *p < 0.05 versus the LPS group; **p < 0.01 versus the LPS group; ***p <








onpredominate in CNS.23 RNAi was performed to determinewhether either a7
nAChR or a4b2 nAChR are involved in inhibition of LPS-induced pro-inflam-
matory factors in microglial BV-2 cells by either nicotine or cotinine. Stable
a7,a4, andb2 subunits of nAChRknockingdowncell lineswere constructed
by lentivirus transduction and puromycin selection. Western blot analysis
showed that a7 nAChR (Figure 5A), as well as a4 and b2 subunits (Fig-
ure S10A), were knocked down by 70%–90% by RNAi compared with
the mock control. a7 nAChR knockdown did not block either nicotine (Fig-
ure 5B) or cotinine (Figure 5C) inhibition of LPS-induced NO. Knockdown
of a4 and b2 subunits also failed to affect nicotine and cotinine inhibition
of LPS-induced NO (Figure S10B). To substantiate the results from the
RNAi, mecamylamine (Mec), which is an nAChR antagonist with non-selec-
tivity toward individual isotypes,24 was used to pharmacologically block
nAChRs to define whether this would disrupt nicotine and cotinine actions
in inhibiting LPS-induced pro-inflammatory factors. It should be noted that
the typical working concentration of Mec is 10 mM.5 Neither 10 nor 50 mM
Mec treatment attenuated nicotine (Figure 5D) or cotinine (Figure 5E) inhibi-
tion of LPS-induced NO in BV-2 cells. Mec also did not affect nicotine or co-
tinine inhibition of LPS-induced TNF-a (Figure 5F). These data indicate that
TLR4 inhibition by nicotine and cotinine is independent of their well-known
nAChR targets and support the notion that MD2 is a novel target of nicotine
and cotinine in the inhibition of innate immunity.
DISCUSSION
Based on the innate immune recognition of TLR4 with psychoactive sub-
stances including morphine,8 cocaine,9 and methamphetamine,10,25 as well
as other MD2 ligands,26–32 XAMPs have been proposed as one type of
TLR4 ligand, beyond the classic PAMPs and DAMPs.2 Nicotine is the major
addictive component of tobacco and belongs to a class of drugs that is sec-
ond only to opioids in addiction liability.33 Herein, we are interested in whether6 The Innovation 2, 100111, May 28, 2021nicotine and its main metabolite cotinine could be recognized by TLR4/MD2
as XAMPs.MD2-intrinsic fluorescence titrations, SPR, and curcumin compet-
itive displacement binding assays showed that both nicotine and its metabo-
lite cotinine targeted the LPS binding pocket of MD2 with similar affinities,
whichwas further supportedbybindingmodeanalysisandMM-PBSA freeen-
ergy calculations during MD simulations. CETSA found that nicotine binding
increased theMD2 thermal stability while cotinine decreased theMD2 stabil-
ity, which is consistent with MD2 RMSD analysis that nicotine binding stabi-
lized the MD2 conformation and cotinine increased the flexibility of MD2.
Compared with nicotine, cotinine was more flexible in the ligand-MD2 com-
plex as revealed by ligand RMSD analysis, which agreed well with the specu-
lation derived from the STD-NMR that cotinine would have a faster exchange
between the free form and the MD2 bound state compared with nicotine. In
agreement with the conclusion from CETSA, in silico simulations found that
nicotine binding increased the percentage of hydrophobic areas in the buried
SASA ofMD2, while cotinine decreased the percentage of hydrophobic areas
in the buried SASA, although the bindings of nicotine and cotinine showed no
significant effect to the total SASA, the buried SASA, or the exposed SASA.
These computational simulations rationalize the opposite behaviors of nico-
tine and cotinine onMD2 from thebiophysical chemistry perspective. In keep-
ing with targeting MD2, nicotine and cotinine inhibited induction of NO and
TNF-a and blocked microglial phagocytosis by the TLR4 agonist LPS.
Nicotine is the principal alkaloid of tobacco,34 and approximately 70%–
80% of nicotine is converted to cotinine, which has a long half-life and does
not have cardiovascular or addictive side effects.35 Smoking a cigarette
yields about 1–2 mg of absorbed nicotine, which is readily transported to
the brain with the concentration of 300 nM.36 Nicotine interacts with
nAChRs and acts as a cholinergic agonist with affinities of nM to low
mM,35 while the affinity of cotinine for nAChRs is >100-fold less potent




Innovationfor the nicotine- and cotinine-induced behavioral responses as measured by
the delayed-matching-to-sample task in animals, wherein cotinine is30- to
2,000-fold less effective than nicotine.38 Here, nicotine and cotinine were
found to be specifically recognized by TLR4 accessory protein MD2 with
similar binding affinities, although they showed opposite effects on the
MD2 protein stability and flexibility. In contrast to cotinine showing much
less nAChR agonist activity than nicotine, cotinine was slightly more potent
in inhibiting LPS-induced pro-inflammatory factors compared with nicotine
in microglial BV-2 cells. Considering the contrasting behaviors of nicotine
and cotinine toward nAChRs,37,38 it is unlikely that the classic nAChR-medi-
ated cholinergic anti-inflammatory pathway was responsible for nicotine
and cotinine inhibiting LPS-induced inflammation in BV-2 cells. Blocking
nAChRs by RNAi (a7, a4, and b2 subunits) and by the pan nAChR inhibitor
Mec did not alter the suppressive effect of nicotine and cotinine, which sup-
ports the conclusion that nAChRs are unlikely to be the targets of nicotine and
cotinine in suppressing the LPS-induced inflammation in microglial BV-
2 cells.
In sum, this study provides direct evidence that the anti-neuroinflamma-
tory effect of nicotine and cotinine is, at least in part, mediated by the inhibi-
tion of TLR4 signaling. Nicotine and cotinine target the LPS binding pocket of
MD2, albeit behaving differently onMD2 stability. Nicotine and cotinine inhibit
LPS-induced NO and TNF-a and block microglial activation as reflected by
enhanced phagocytosis. Neither RNAi of nAChRs nor pan nAChR inhibition
abolish either nicotine- or cotinine-inducedsuppressive effect of neuroinflam-
mation. These data indicate that TLR4 inhibition by nicotine and cotinine at
the concentrations tested in BV-2 cells is independent of classic nAChRs
and validate that MD2 is a direct target of nicotine and cotinine in the inhibi-
tion of innate immunity. This work furthers our understanding of the mecha-
nisms underlying the nicotine neuroimmunomodulation, which would be of
paramount importance for its translational applications.MATERIALS AND METHODS
Materials
Nicotine, cotinine, curcumin, roxithromycin, 2,3-diaminonaphthalene, anti-GAPDH
primary antibody, and anti-b-actin antibody were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Ultrapure LPS and puromycin were obtained from Invivogen (San
Diego, CA, USA). The Vybrant Phagocytosis Assay Kit, the Quantitative Peroxide Assay
Kit, RIPA buffer, protease inhibitor cocktails, and SuperSignal West Pico Chemilumi-
nescent Substrate were purchased from Thermo Fisher Scientific (Waltham, MA,
USA). TheRNeasyMini Kit, the RT2 Easy First Strand cDNASynthesis Kit, PCR primers,
and SYBR Green PCR Master Mix were obtained from QIAGEN (Frederick, MD, USA).
Primary MD2 antibody, TLR4 antibody, anti-a7 nAChR antibody, anti-b2 nAChR anti-
body, and anti-a4 nAChR antibody were purchased from Abcam (Cambridge, MA,
USA). Anti-IL6 antibody was purchased from ImmunoWay (Plano, TX, USA); anti-
IRAK1 antibody was purchased from Proteintech (Wuhan, Hubei, China); anti-Phos-
pho-IRAK1 (Thr209) antibody, and anti-COX2 antibody were purchased from Abways
Technology (Shanghai, China); anti-MyD88 antibody, anti-IRAK4 antibody, anti-Phos-
pho-IRAK4 (Thr345/Ser346) antibody, anti-IKKb, anti-Phospho-IKKa/b (Ser176/180)
antibody, anti-p38 MAPK antibody, anti-Phospho-p38 MAPK (Thr180/Tyr182) anti-
body, anti-NF-kB p65 antibody, and anti-Phospho-NF-kB p65 (Ser536) antibody were
purchased from Cell Signaling Technology (Danvers, MA, USA). The TNF-a ELISA kit
and the TMB substrate reagent set were purchased from BD Biosciences (San Jose,
CA, USA). Well-characterized a7 nAChR (a7 nAChR) shRNA lentiviral transduction par-
ticles (TRCN0000102955), b2 nAChR shRNA lentiviral transduction particles
(TRCN0000103020), a4 nAChR shRNA lentiviral transduction particles (TRCN
0000102860), and mock control transduction particles were obtained from the Func-
tional Genomic Facility in the BioFrontiers Institute of the University of Colorado at
Boulder under the license of Sigma-Aldrich (St. Louis, MO, USA).Methods
More information is available in the supplemental information file.
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